Similar Outcomes of Surgical and Medical Treatment of Intra-abdominal Abscesses in Patients With Crohn's Disease

Douglas L. Nguyen, William J. Sandborn, Edward Vincent Loftus, Jr, David Larson, Joel Garland Fletcher, Brenda Becker, Jayawant Mandrekar, William S. Harmsen, David H. Bruining

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background & Aims: It is not clear whether medical therapy, surgery, or both is the best approach for patients with Crohn's disease who develop an intra-abdominal abscess. Methods: We evaluated data from patients with Crohn's disease who were diagnosed with a radiologically confirmed abdominal abscess (enhancing fluid collection, ≥1 cm) from 1999 to 2006 (n = 95; median age, 42.0 y; 50.5% female). Medical/nonsurgical methods (percutaneous aspiration ± drain placement) were used for 55 patients (mean abscess size, 6.9 ± 3.2 cm), and 40 patients underwent surgical interventions (laparotomy ± bowel resection; mean abscess size, 7.5 ± 3.7 cm). We investigated risk factors for abscess recurrence. Results: The median length of hospitalization was 15.5 days for patients who underwent surgery and 5.0 days for patients who did not (P < .001). The 5-year cumulative probability of abscess recurrence was 31.2% among patients who did not undergo surgery and 20.3% among those who did (P = .25). Histories of perianal or active ileal disease predicted abscess recurrence. Initiation of pharmacologic therapy after drainage reduced the risk for abscess recurrence (P < .001). Anti-tumor necrosis factor therapy, compared with no therapy, reduced the risk of abscess recurrence (P = .001) in all patients, whereas immunosuppressive monotherapy, compared with no therapy, had a trend toward significant risk reduction (P = .06). Conclusions: Among patients with Crohn's disease who have intra-abdominal abscesses, nonsurgical and primary surgical management strategies result in similar rates of abscess recurrence and complications. Initiation of anti-tumor necrosis factor and/or immunosuppressive therapy when abscesses resolve might protect against intra-abdominal penetrating disease.

Original languageEnglish (US)
Pages (from-to)400-404
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume10
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Abdominal Abscess
Crohn Disease
Abscess
Recurrence
Therapeutics
Immunosuppressive Agents
Ileal Diseases
Tumor Necrosis Factor-alpha
Risk Reduction Behavior
Ambulatory Surgical Procedures
Laparotomy
Drainage
Hospitalization

Keywords

  • Anti-TNF therapy
  • IBD
  • Inflammatory bowel disease
  • Management

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Similar Outcomes of Surgical and Medical Treatment of Intra-abdominal Abscesses in Patients With Crohn's Disease. / Nguyen, Douglas L.; Sandborn, William J.; Loftus, Jr, Edward Vincent; Larson, David; Fletcher, Joel Garland; Becker, Brenda; Mandrekar, Jayawant; Harmsen, William S.; Bruining, David H.

In: Clinical Gastroenterology and Hepatology, Vol. 10, No. 4, 04.2012, p. 400-404.

Research output: Contribution to journalArticle

@article{11893b55870e42229038ac014e3169a3,
title = "Similar Outcomes of Surgical and Medical Treatment of Intra-abdominal Abscesses in Patients With Crohn's Disease",
abstract = "Background & Aims: It is not clear whether medical therapy, surgery, or both is the best approach for patients with Crohn's disease who develop an intra-abdominal abscess. Methods: We evaluated data from patients with Crohn's disease who were diagnosed with a radiologically confirmed abdominal abscess (enhancing fluid collection, ≥1 cm) from 1999 to 2006 (n = 95; median age, 42.0 y; 50.5{\%} female). Medical/nonsurgical methods (percutaneous aspiration ± drain placement) were used for 55 patients (mean abscess size, 6.9 ± 3.2 cm), and 40 patients underwent surgical interventions (laparotomy ± bowel resection; mean abscess size, 7.5 ± 3.7 cm). We investigated risk factors for abscess recurrence. Results: The median length of hospitalization was 15.5 days for patients who underwent surgery and 5.0 days for patients who did not (P < .001). The 5-year cumulative probability of abscess recurrence was 31.2{\%} among patients who did not undergo surgery and 20.3{\%} among those who did (P = .25). Histories of perianal or active ileal disease predicted abscess recurrence. Initiation of pharmacologic therapy after drainage reduced the risk for abscess recurrence (P < .001). Anti-tumor necrosis factor therapy, compared with no therapy, reduced the risk of abscess recurrence (P = .001) in all patients, whereas immunosuppressive monotherapy, compared with no therapy, had a trend toward significant risk reduction (P = .06). Conclusions: Among patients with Crohn's disease who have intra-abdominal abscesses, nonsurgical and primary surgical management strategies result in similar rates of abscess recurrence and complications. Initiation of anti-tumor necrosis factor and/or immunosuppressive therapy when abscesses resolve might protect against intra-abdominal penetrating disease.",
keywords = "Anti-TNF therapy, IBD, Inflammatory bowel disease, Management",
author = "Nguyen, {Douglas L.} and Sandborn, {William J.} and {Loftus, Jr}, {Edward Vincent} and David Larson and Fletcher, {Joel Garland} and Brenda Becker and Jayawant Mandrekar and Harmsen, {William S.} and Bruining, {David H.}",
year = "2012",
month = "4",
doi = "10.1016/j.cgh.2011.11.023",
language = "English (US)",
volume = "10",
pages = "400--404",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Similar Outcomes of Surgical and Medical Treatment of Intra-abdominal Abscesses in Patients With Crohn's Disease

AU - Nguyen, Douglas L.

AU - Sandborn, William J.

AU - Loftus, Jr, Edward Vincent

AU - Larson, David

AU - Fletcher, Joel Garland

AU - Becker, Brenda

AU - Mandrekar, Jayawant

AU - Harmsen, William S.

AU - Bruining, David H.

PY - 2012/4

Y1 - 2012/4

N2 - Background & Aims: It is not clear whether medical therapy, surgery, or both is the best approach for patients with Crohn's disease who develop an intra-abdominal abscess. Methods: We evaluated data from patients with Crohn's disease who were diagnosed with a radiologically confirmed abdominal abscess (enhancing fluid collection, ≥1 cm) from 1999 to 2006 (n = 95; median age, 42.0 y; 50.5% female). Medical/nonsurgical methods (percutaneous aspiration ± drain placement) were used for 55 patients (mean abscess size, 6.9 ± 3.2 cm), and 40 patients underwent surgical interventions (laparotomy ± bowel resection; mean abscess size, 7.5 ± 3.7 cm). We investigated risk factors for abscess recurrence. Results: The median length of hospitalization was 15.5 days for patients who underwent surgery and 5.0 days for patients who did not (P < .001). The 5-year cumulative probability of abscess recurrence was 31.2% among patients who did not undergo surgery and 20.3% among those who did (P = .25). Histories of perianal or active ileal disease predicted abscess recurrence. Initiation of pharmacologic therapy after drainage reduced the risk for abscess recurrence (P < .001). Anti-tumor necrosis factor therapy, compared with no therapy, reduced the risk of abscess recurrence (P = .001) in all patients, whereas immunosuppressive monotherapy, compared with no therapy, had a trend toward significant risk reduction (P = .06). Conclusions: Among patients with Crohn's disease who have intra-abdominal abscesses, nonsurgical and primary surgical management strategies result in similar rates of abscess recurrence and complications. Initiation of anti-tumor necrosis factor and/or immunosuppressive therapy when abscesses resolve might protect against intra-abdominal penetrating disease.

AB - Background & Aims: It is not clear whether medical therapy, surgery, or both is the best approach for patients with Crohn's disease who develop an intra-abdominal abscess. Methods: We evaluated data from patients with Crohn's disease who were diagnosed with a radiologically confirmed abdominal abscess (enhancing fluid collection, ≥1 cm) from 1999 to 2006 (n = 95; median age, 42.0 y; 50.5% female). Medical/nonsurgical methods (percutaneous aspiration ± drain placement) were used for 55 patients (mean abscess size, 6.9 ± 3.2 cm), and 40 patients underwent surgical interventions (laparotomy ± bowel resection; mean abscess size, 7.5 ± 3.7 cm). We investigated risk factors for abscess recurrence. Results: The median length of hospitalization was 15.5 days for patients who underwent surgery and 5.0 days for patients who did not (P < .001). The 5-year cumulative probability of abscess recurrence was 31.2% among patients who did not undergo surgery and 20.3% among those who did (P = .25). Histories of perianal or active ileal disease predicted abscess recurrence. Initiation of pharmacologic therapy after drainage reduced the risk for abscess recurrence (P < .001). Anti-tumor necrosis factor therapy, compared with no therapy, reduced the risk of abscess recurrence (P = .001) in all patients, whereas immunosuppressive monotherapy, compared with no therapy, had a trend toward significant risk reduction (P = .06). Conclusions: Among patients with Crohn's disease who have intra-abdominal abscesses, nonsurgical and primary surgical management strategies result in similar rates of abscess recurrence and complications. Initiation of anti-tumor necrosis factor and/or immunosuppressive therapy when abscesses resolve might protect against intra-abdominal penetrating disease.

KW - Anti-TNF therapy

KW - IBD

KW - Inflammatory bowel disease

KW - Management

UR - http://www.scopus.com/inward/record.url?scp=84858703024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858703024&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2011.11.023

DO - 10.1016/j.cgh.2011.11.023

M3 - Article

C2 - 22155562

AN - SCOPUS:84858703024

VL - 10

SP - 400

EP - 404

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 4

ER -